Unit Dose Valsartan Tablets
Recall D-0967-2018, part of FDA recall event 80557. See Major Pharmaceuticals's company page.
MAJOR PHARMACEUTICALS started this Class II drug recall on Jul 18, 2018 (n/a); FDA lists it as terminated, terminated Oct 2, 2022.
- Classification: Class II
- Started: Jul 18, 2018
- Status: Terminated
- Products in this event: 2
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
- Product
- Unit Dose Valsartan Tablets, USP. 160 mg. Rx only.,Distributed by: Major Pharmaceuticals, Livonia, MI 48152, NDC# 0904-6594-61. NDC# 0904-6595-61.
- Quantity
- 4,556 cartons
- Lots and codes
- Major Label Unit Dose 10 x 10 Cartons 160 mg Item # 302087. Lot# T-01269 (Expiry: 7/18). Lot# T-01524 (Expiry: 2/19). Lot# T-01646 (Expiry: 5/19). Lot# T-01668 (Expiry: 5/19). Lot# T-01788 (Expiry: 5/19).
- Distribution
- Nationwide.
- Recalling firm
- MAJOR PHARMACEUTICALS, Livonia, MI, United States
- How the firm notified
- N/A
- FDA classified
- Jul 20, 2018
- Unit Dose Valsartan Tablets, USP, 80 mg. Rx only, Distributed by: Major Pharmaceuticals, Livonia, MI 48152, NDC#…D-0966-2018 · Class II · Jul 18, 2018 · Terminated
Newest first, one product per recall event; search them all
- DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS, USP Tablets, 250 mg, 100 count-unit dose carton, RX only, Manufactured by…D-1583-2019 · Class II · Apr 24, 2019 · Terminated
- Losartan Potassium Tablets, USP. 50 mg. NDC# 0904-6390-61. Rx only. 100 count Unit Dose Cartons. Manufactured by Major…D-1466-2019 · Class II · Jan 10, 2019 · Terminated
- Doxycycline Hyclate Tablets, USP, 100 mg, Rx Only, 30 tablets, 3 x 10 unit dose Cartons, Mfd. by: West-Ward…D-1026-2018 · Class II · Jul 30, 2018 · Terminated
- Enalapril Maleate Tablets, USP, 2.5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt…D-0979-2018 · Class III · Jun 26, 2018 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports